ENG/中
老虎证券
行情
产品介绍
Cash Boost账户
美股
美股碎股
港股
A股通
期权
期货
美国国债
定投
固定票息票据
Tiger BOSS Debit Card
基金超市
老虎钱袋子
老虎API平台
Wealth
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
专栏
TigerAI
机构
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
登录
立即注册
Toggle
美股
详情
本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务
Bayer A.G.
6.85
+0.0000
成交量:
- -
成交额:
- -
市值:
269.18亿
市盈率:
-10.18
高:
6.85
开:
6.85
低:
6.85
收:
6.85
数据加载中...
总览
公司
新闻
公告
概念
没有相关数据
资金流向
资金流入:
资金流出:
实时
日
周
月
季度
年
新闻
拜耳第四季度每股收益调整值为$0.28,低于$1.00的预期,销售额为$125.2亿,高于$113.0亿的预期
财报速递
·
03-05
拜耳(BAYRY.US)非奈利酮片新适应症在华上市申请获理
智通财经
·
01-24
拜耳(BAYRY.US)“达罗他胺”新适应症在美申报上市
智通财经
·
2024-11-22
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BAYRY"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BAYRY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BAYRY\",,,,,undefined,":{"symbol":"BAYRY","market":"US","secType":"STK","nameCN":"Bayer A.G.","latestPrice":6.85,"timestamp":1746475200000,"preClose":6.85,"halted":0,"volume":0,"delay":15,"floatShares":3929259738,"shares":3929696328,"eps":-0.672948,"marketStatus":"交易中","change":0,"latestTime":"05-05 16:00:00 EDT 延时","open":6.85,"high":6.85,"low":6.85,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.672948,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1746561600000},"marketStatusCode":2,"adr":0,"adrRate":0.25,"exchange":"PINK","adjPreClose":6.85,"volumeRatio":0.9440398064694809},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BAYRY\",,,,,undefined,":{"symbol":"BAYRY","floatShares":3929259738,"roa":"3.00%","roe":"-7.82%","lyrEps":-0.672948,"volumeRatio":0.9440398064694809,"shares":3929696328,"dividePrice":0.031183,"high":6.85,"amplitude":0,"preClose":6.85,"low":6.85,"week52Low":4.79,"pbRate":"0.74","psRate":"0.51","week52High":8.58,"institutionHeld":0,"latestPrice":6.85,"eps":-0.672948,"divideRate":0.004552,"volume":0,"delay":15,"ttmEps":-0.672948,"open":6.85,"prevYearClose":4.88,"prevWeekClose":6.74,"prevMonthClose":6.59,"prevQuarterClose":6.02,"fiveDayClose":6.6,"twentyDayClose":5.45,"sixtyDayClose":5.42,"earningDate":1747065600000},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/BAYRY\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BAYRY\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1154866640","title":"拜耳第四季度每股收益调整值为$0.28,低于$1.00的预期,销售额为$125.2亿,高于$113.0亿的预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1154866640","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154866640?lang=zh_cn&edition=fundamental","pubTime":"2025-03-05 19:19","pubTimestamp":1741173549,"startTime":"0","endTime":"0","summary":"拜耳公布的季度每股收益为$0.28,较分析师一致预期的$1.00低出72%,与去年同期的每股收益$0.50相比下降了44%。以上内容来自Benzinga Earnings专栏,原文如下:Bayer reported quarterly earnings of $0.28 per share which missed the analyst consensus estimate of $1.00 by 72 percent. This is a 44 percent decrease over earnings of $0.50 per share from the same period last year. The company reported quarterly sales of $12.52 billion which beat the analyst consensus estimate of $11.30 billion by 10.81 percent. This is a 1.96 percent decrease over sales of $12.77 bi","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"拜耳第四季度每股收益调整值为$0.28,低于$1.00的预期,销售额为$125.2亿,高于$113.0亿的预期","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY"],"gpt_icon":1},{"id":"2505632885","title":"拜耳(BAYRY.US)非奈利酮片新适应症在华上市申请获理","url":"https://stock-news.laohu8.com/highlight/detail?id=2505632885","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505632885?lang=zh_cn&edition=fundamental","pubTime":"2025-01-24 14:38","pubTimestamp":1737700694,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,1月24日,中国国家药监局药品审评中心官网最新公示,拜耳非奈利酮片的新适应症上市申请获得受理。具体而言,试验结果显示,在LVEF≥40%的心力衰竭患者中,非奈利酮将心血管死亡和总心力衰竭事件构成的复合临床指标降低16%,达成试验主要终点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1243237.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"拜耳(BAYRY.US)非奈利酮片新适应症在华上市申请获理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BAYRY","BK4007"],"gpt_icon":0},{"id":"2485250944","title":"拜耳(BAYRY.US)“达罗他胺”新适应症在美申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2485250944","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485250944?lang=zh_cn&edition=fundamental","pubTime":"2024-11-22 21:06","pubTimestamp":1732280762,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,11月21日,拜耳(BAYRY.US)宣布其达罗他胺(商品名:Nubeqa)联合雄激素剥夺疗法(ADT)治疗转移性激素敏感性前列腺癌(mHSPC)患者的补充新药申请(sNDA)获FDA受理。此次sNDA是基于III期ARANOTE研究的积极结果。该研究是一项随机、双盲、安慰剂对照临床试验(n=669),评估了达罗他胺(600mg,每日2次)联合ADT对比安慰剂联合ADT治疗mHSPC患者的疗效和安全性。研究的主要终点是第36个月的放射学无进展生存期(rPFS)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1214939.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BAYRY","BK4007"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":3,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BAYRY\",params:#limit:5,,,undefined,":[{"date":"2025-05-13","symbol":"BAYRY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1747123200000,"name":null,"time":"","dateTimestamp":1747108800000,"actualEps":null},{"date":"2025-04-29","symbol":"BAYRY","amount":0.030365,"announcedDate":"2025-04-04","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-29","defaultRemindTime":1745933400000,"name":"Bayer A.G.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-12","payableDate":"2025-04-29","currency":"USD","dateTimestamp":1745899200000,"payDate":"2025-05-12"},{"market":"US","date":"2024-11-12","symbol":"BAYRY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"","actualEps":null},{"date":"2024-08-06","symbol":"BAYRY","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1722974400000,"name":null,"time":"盘后","dateTimestamp":1722916800000,"actualEps":null},{"date":"2024-05-14","symbol":"BAYRY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1715673600000,"name":null,"time":"","dateTimestamp":1715659200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BAYRY\",market:\"US\",,,undefined,":[{"executeDate":"2015-05-22","recordDate":"2015-05-27","paymentDate":"2015-06-08","value":1.791948,"currency":"USD"},{"executeDate":"2016-04-27","recordDate":"2016-04-29","paymentDate":"2016-05-12","value":2.091196,"currency":"USD"},{"executeDate":"2019-04-29","recordDate":"2019-04-30","paymentDate":"2019-05-13","value":0.550569,"currency":"USD"},{"executeDate":"2020-04-29","recordDate":"2020-04-30","paymentDate":"2020-05-14","value":0.535933,"currency":"USD"},{"executeDate":"2021-04-28","recordDate":"2021-04-29","paymentDate":"2021-05-10","value":0.407111,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BAYRY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0,"hold":0.5,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0,"analysts":2,"updateTime":1746417600000}}}